AliveDx has obtained a CE mark under the EU's in vitro diagnostic regulation (IVDR) for the AiPlex connective tissue disease ...

MosaiQ, Quotient's next-generation platform is designed to deliver fast, comprehensive antigen typing, antibody detection and disease screening results, using a single low volume sample in a high ...

The National Screening Laboratory of Sanquin Blood Supply Foundation joins MosaiQ Innovator’s Circle JERSEY, Channel Islands, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ ...

MoSAIQ-Market Neutral NM is an all-weather, market neutral, absolute return strategy that relies on behavioral finance and AI, and is based on contra consensual paradigms, i.e. concepts that are at ...

MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities.

Quotient's MosaiQ diagnostic platform is set to be approved in the US this year. However, the stock does not seem to be drawing much investor attention. Despite having a good product and a strong ...

ATLANTA, Aug. 11, 2011 /PRNewswire/ -- The seamless integration of Elekta's MOSAIQ® Oncology Information System (OIS)* and Varian's TrueBeam™ radiation therapy system is enabling the ...

EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ — AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac ...

Tools developed through this investment will provide customers with innovative solutions that are fully integrated with Elekta's MOSAIQ® Oncology Information System to address the growing need ...

QTNT has an existing revenue stream from approved reagents. However, its MosaiQ platform is its biggest potential. Despite trading at 52-week highs, QTNT has solid prospects. Looking for more ...